Colonic mucosal immune activity in irritable bowel syndrome: Comparison with healthy controls and patients with ulcerative colitis

Digestive Diseases and Sciences

Volumn 59, Issue 5, 2014, Pages 1001-1011

  Ahn, Ji Yong ^a,b   Lee, Kyung Hun ^a   Choi, Chang Hwan ^a   Kim, Ju Wan ^a   Lee, Hyun Woong ^a   Kim, Jeong Wook ^a   Kim, Mi Kyung ^a   Kwon, Gui Young ^a   Han, Seungbong ^b   Kim, Seong Eun ^c   Kim, Sung Min ^d   Chang, Sae Kyung ^a  

^a Chung Ang University College of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Ewha Womans University School of Medicine   (South Korea)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Irritable bowel syndrome; Mast cell; T cell; Ulcerative colitis

Indexed keywords

ADULT; ARTICLE; COLON BIOPSY; COLON MUCOSA; COLONOSCOPY; CONTROLLED STUDY; DIARRHEA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; INTRAEPITHELIAL LYMPHOCYTE; IRRITABLE COLON; LAMINA PROPRIA; LAMINA PROPRIAL LYMPHOCYTE; LYMPHOCYTE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MAST CELL; MUCOSAL IMMUNE ACTIVATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; REMISSION; SHORT FORM 36; ULCERATIVE COLITIS;

ADULT; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; COLON; FEMALE; HEALTH SURVEYS; HUMANS; INTESTINAL MUCOSA; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 84899905703     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-013-2930-4     Document Type: Article

References (48)

1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130:1480-1491.
2. Cremon C, Gargano L, Morselli-Labate AM, et al. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol. 2009;104:392-400.
3. Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004;126: 693-702. (Pubitemid 38298317)
4. Wang LH, Fang XC, Pan GZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut. 2004;53:1096-1101.
5. Dunlop SP, Jenkins D, Spiller RC. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol. 2003;98:1578-1583. (Pubitemid 36875351)
6. Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in postdysenteric irritable bowel syndrome. Gut. 2000;47:804-811.
7. Lee KJ, Kim YB, Kim JH, Kwon HC, Kim DK, Cho SW. The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors. J Gastroenterol Hepatol. 2008;23:1689-1694.
8. Wheatcroft J, Wakelin D, Smith A, Mahoney CR, Mawe G, Spiller R. Enterochromaffin cell hyperplasia and decreased serotonin transporter in a mouse model of postinfectious bowel dysfunction. Neurogastroenterol Motil. 2005;17:863-870. (Pubitemid 41748282)
9. Park JH, Rhee PL, Kim HS, et al. Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome. J Gastroenterol Hepatol. 2006;21:71-78.
10. Barbara G, Wang B, Stanghellini V, et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology. 2007;132:26-37. (Pubitemid 46108761)
11. Cenac N, Andrews CN, Holzhausen M, et al. Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest. 2007;117:636-647. (Pubitemid 46348522)
12. Barbara G, De Giorgio R, Stanghellini V, Cremon C, Corinaldesi R. A role for inflammation in irritable bowel syndrome? Gut. 2002;51:i41-i44. (Pubitemid 34717718)
13. Burgmann T, Clara I, Graff L, et al. The Manitoba Inflammatory Bowel Disease Cohort Study: prolonged symptoms before diagnosis - how much is irritable bowel syndrome? Clin Gastroenterol Hepatol. 2006;4:614-620.
14. Limsui D, Pardi DS, Camilleri M, et al. Symptomatic overlap between irritable bowel syndrome and microscopic colitis. Inflamm Bowel Dis. 2007;13:175-181. (Pubitemid 46806226)
15. Simren M, Axelsson J, Gillberg R, Abrahamsson H, Svedlund J, Bjornsson ES. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol. 2002;97:389-396. (Pubitemid 34160766)
16. Choi CH, Jung SA, Lee BI, Lee KM, Kim JS, Han DS. Diagnostic guideline of ulcerative colitis. Korean J Gastroenterol. 2009;53:145-160.
17. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology. Practice Parameters Committee. Am J Gastroenterol. 2004;99:1371-1385. (Pubitemid 39062279)
18. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501-523; quiz 524.
19. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625-1629. (Pubitemid 18010466)
20. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128:541-551. (Pubitemid 40585355)
21. Veldhuyzen van Zanten SJ, Talley NJ, Bytzer P, Klein KB, Whorwell PJ, Zinsmeister AR. Design of treatment trials for functional gastrointestinal disorders. Gut. 1999;45:II69-77. (Pubitemid 29434816)
22. Ware JE Jr. Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-483.
23. Patrick DL, Drossman DA, Frederick IO, DiCesare J, Puder KL. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci. 1998;43:400-411. (Pubitemid 28124621)
24. Park JM, Choi MG, Oh JH, et al. Cross-cultural validation of Irritable Bowel Syndrome Quality of Life in Korea. Dig Dis Sci. 2006;51:1478-1484. (Pubitemid 44315818)
25. Ohman L, Isaksson S, Lindmark AC, et al. T-cell activation in patients with irritable bowel syndrome. Am J Gastroenterol. 2009;104:1205-1212.
26. Vivinus-Nebot M, Dainese R, Anty R, et al. Combination of allergic factors can worsen diarrheic irritable bowel syndrome: role of barrier defects and mast cells. Am J Gastroenterol. 2012;107:75-81.
27. De Silva AP, Nandasiri SD, Hewavisenthi J, et al. Subclinical mucosal inflammation in diarrhea-predominant irritable bowel syndrome (IBS) in a tropical setting. Scand J Gastroenterol. 2012;47:619-624.
28. Bashashati M, Rezaei N, Bashashati H, et al. Cytokine gene polymorphisms are associated with irritable bowel syndrome: a systematic review and meta-analysis. Neurogastroenterol Motil. 2012;24:1102-e1566.
29. Yamagata K, Tanaka M, Kudo H. A quantitative immunohisto-chemical evaluation of inflammatory cells at the affected and unaffected sites of inflammatory bowel disease. J Gastroenterol Hepatol. 1998;13:801-808. (Pubitemid 28374896)
30. Quist RG, Ton-Nu HT, Lillienau J, Hofmann AF, Barrett KE. Activation of mast cells by bile acids. Gastroenterology. 1991;101:446-456.
31. Gui XY. Mast cells: a possible link between psychological stress, enteric infection, food allergy and gut hypersensitivity in the irritable bowel syndrome. J Gastroenterol Hepatol. 1998;13: 980-989.
32. El-Salhy M, Gundersen D, Hatlebakk JG, Hausken T. Low-grade inflammation in the rectum of patients with sporadic irritable bowel syndrome. Mol Med Rep. 2013;7:1081-1085.
33. Weston AP, Biddle WL, Bhatia PS, Miner PB Jr. Terminal ileal mucosal mast cells in irritable bowel syndrome. Dig Dis Sci. 1993;38:1590-1595. (Pubitemid 23271411)
34. O'Sullivan M, Clayton N, Breslin NP, et al. Increased mast cells in the irritable bowel syndrome. Neurogastroenterol Motil. 2000;12:449-457.
35. Nishida Y, Murase K, Isomoto H, et al. Different distribution of mast cells and macrophages in colonic mucosa of patients with collagenous colitis and inflammatory bowel disease. Hepatogastroenterology. 2002;49:678-682. (Pubitemid 34615326)
36. van Hoboken EA, Thijssen AY, Verhaaren R, et al. Symptoms in patients with ulcerative colitis in remission are associated with visceral hypersensitivity and mast cell activity. Scand J Gastroenterol. 2011;46:981-987.
37. Liebregts T, Adam B, Bredack C, et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology. 2007;132:913-920. (Pubitemid 46440872)
38. Dinan TG, Quigley EM, Ahmed SM, et al. Hypothalamic-pitui-tary- gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology. 2006;130:304-311. (Pubitemid 43202030)
39. Chadwick VS, Chen W, Shu D, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology. 2002;122:1778-1783. (Pubitemid 34651421)
40. Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology. 2003;125:1651-1659. (Pubitemid 37500429)
41. Arevalo F, Aragon V, Montes P, Guzman E, Monge E. Increase of intraepithelial lymphocytes in patients with irritable bowel syndrome. Rev Gastroenterol Peru. 2011;31:315-318.
42. Reichman-Warmusz E, Kurek J, Gabriel A, et al. Tissue hemostasis and chronic inflammation in colon biopsies of patients with inflammatory bowel disease. Pathol Res Pract. 2012;208: 553-556.
43. Dai SX, Wu G, Zou Y, et al. Balance of CD8(?)CD28 (?)/CD8 (?)CD28 (-) T lymphocytes is vital for patients with ulcerative colitis. Dig Dis Sci. 2013;58:88-96.
44. Cho HS, Park JM, Lim CH, et al. Anxiety, depression and quality of life in patients with irritable bowel syndrome. Gut Liver. 2011;5:29-36.
45. Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology . 2000;119:654-660.
46. Whitehead WE, Burnett CK, Cook EW III, Taub E. Impact of irritable bowel syndrome on quality of life. Dig Dis Sci. 1996;41:2248-2253. (Pubitemid 26414448)
47. Drossman DA, Patrick DL, Mitchell CM, Zagami EA, Appelbaum MI. Health-related quality of life in inflammatory bowel disease. Functional status and patient worries and concerns. Dig Dis Sci. 1989;34:1379-1386. (Pubitemid 19247394)
48. Bercik P, Verdu EF, Collins SM. Is irritable bowel syndrome a low-grade inflammatory bowel disease? Gastroenterol Clin N Am. 2005;34:235-245, vi-vii. (Pubitemid 40615953)